Zytiga Rejected in England as First-line Treatment for Newly Diagnosed Advanced Prostate Cancer

Zytiga Rejected in England as First-line Treatment for Newly Diagnosed Advanced Prostate Cancer
Janssen’s medication Zytiga (abiraterone) was recently rejected as a first-line treatment for newly diagnosed advanced prostate cancer on the National Health Service (NHS) in England following an initial draft recommendation from the National Institute for Health and Care Excellence (NICE). The negative recommendation means Zytiga won’t be made routinely available for men with newly diagnosed metastatic prostate cancer.

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. Felipe says:

    After take Zytiga, I have had lots of energy and felt good until recently. My PSA initially went from 66 to 0.1, after 20 months it has started to rise, now it is 0.8 The medicine was easy to take

    • Alex S. Kimaro says:

      I am a prostate cancer patient,i was treated with ciber knife five circles,i am now doing well proceeding with my daily duties.
      The problem i am having is that my libido is very low,what could be a problem?
      I went to see my oncologist who advised that it will take time to get back to normal!

Leave a Comment

Your email address will not be published. Required fields are marked *